Bayer (BAYRY) Downgraded by Zacks Investment Research to “Hold”

Bayer (OTCMKTS:BAYRY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, January 18th.

According to Zacks, “As part of its strategy to complete the planned acquisition of Monsanto, Bayer inked an agreement to sell selected Crop Science businesses to BASF. With this agreement, the company will actively address the authorities’ possible concerns regarding the planned acquisition of Monsanto and facilitate a successful closing of the transaction by early 2018. The combined enterprise will be able to bring innovations to the market faster and provide its customers with better solutions. However, the company is facing generic competition for many of its products including the Yaz franchise (oral contraceptives). The generics of key drugs will negatively impact revenues. Yet, Bayer’s shares have outperformed the industry year to date. Estimates have increased ahead of the Q4 earnings results. The company has a positive record of earnings surprises in recent quarters.”

BAYRY has been the topic of a number of other research reports. BNP Paribas upgraded Bayer from a “neutral” rating to an “outperform” rating in a research report on Monday, September 25th. ValuEngine downgraded Bayer from a “buy” rating to a “hold” rating in a research report on Friday, September 22nd. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. Bayer presently has a consensus rating of “Hold” and a consensus price target of $36.00.

Shares of Bayer (OTCMKTS BAYRY) traded up $0.24 during trading on Thursday, reaching $29.90. The company had a trading volume of 445,394 shares, compared to its average volume of 462,781. Bayer has a 52-week low of $27.54 and a 52-week high of $35.41. The company has a current ratio of 1.51, a quick ratio of 1.01 and a debt-to-equity ratio of 0.67.

ILLEGAL ACTIVITY NOTICE: “Bayer (BAYRY) Downgraded by Zacks Investment Research to “Hold”” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://ledgergazette.com/2018/02/12/zacks-investment-research-downgrades-bayer-bayry-to-hold.html.

Bayer Company Profile

Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.

Get a free copy of the Zacks research report on Bayer (BAYRY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply